SHORT COMMUNICATION
Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct‐acting antiviral therapy including first‐ and second‐generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin